Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

Experts discuss the role of multidisciplinary teams, gene expression patterns, rare disease drug designation, and education gaps in managing desmoid tumors, emphasizing the need for comprehensive care ...

Parabilis Medicines, Inc.’s IPO spotlights Helicon peptide cancer drugs like zolucatetide, plus Regeneron’s $125M backing & ...

Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

Varegacestat reduced the risk of disease progression or death by 84% compared with placebo in patients with progressing desmoid tumors. Topline data were announced from a phase 3 trial evaluating ...

On April 29, Immunome, Inc. (NASDAQ:IMNM) reported the filing of a new drug application with the US Food and Drug ...

Add Yahoo as a preferred source to see more of our stories on Google. Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s ...

A SpringWorks Therapeutics drug has won FDA approval for treating a rare connective tissue tumor, making it the first approved therapy for this type of tumor. It’s also the first product approval for ...

(RTTNews) - Immunome, Inc. (IMNM) is scheduled to report topline Phase 3 results of its lead drug candidate, Varegacestat, in desmoid tumors, dubbed RINGSIDE trial, today. Desmoid tumors are rare, ...

Credit: SpringWorks. Nirogacestat is an oral, selective, small molecule gamma secretase inhibitor. Treatment with Ogsiveo significantly reduced the risk of disease progression by 71% compared with ...

Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls. Brooke’s mother also had 28 surgeries related to her desmoid tumors and multiple ...